MDWDHealthcare · BiotechnologyThe 6 Wall Street analysts covering MediWound Ltd. hold a median 12-month price target of $31 — +128.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores MediWound Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (80): The share price has been relatively steady.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MDWD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +128.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $36 |
| 28 May 2026 | Oppenheimer | Maintains | Outperform | $33 → $32 |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | Craig-Hallum | Initiates | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Sept 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Aug 2023 | Oppenheimer | Maintains | Outperform | — |
| 31 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2023 | Oppenheimer | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDWD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 11% of US stocks
Cheaper than 26% of US stocks
Cheaper than 78% of US stocks
Higher than 6% of US stocks
Higher than 24% of US stocks
Higher than 9% of US stocks
Higher than 3% of US stocks
Higher than 17% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MediWound Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MediWound Ltd. held its second-quarter 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The item confirms the call took place and provides access to the company's discussion of its quarterly results.
Why it matters — MDWD watchers can review management's commentary on the company's Q2 2026 performance and outlook directly from the transcript.
MediWound reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier. The company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
Why it matters — MDWD watchers would care because the lower quarterly revenue and ongoing spending on the Phase III EscharEx and NexoBrid programs signal the company's current financial position and its continued focus on advancing its pipeline development.
MediWound reported a Q2 loss of $0.77 per share, slightly wider than the Zacks Consensus Estimate of a $0.76 loss but narrower than the $1.23 per share loss reported a year earlier. Revenue for the quarter beat analyst estimates.
Why it matters — The narrower year-over-year loss and revenue beat may signal improving financial performance for MediWound, though the quarterly loss still came in slightly above consensus expectations.
MediWound reported second quarter 2026 revenue of $3.1 million and reaffirmed full-year 2026 revenue guidance of $24–26 million. The EscharEx Phase III VALUE trial is advancing, with interim assessment and enrollment completion expected by end of the first quarter of 2027, and the company signed a Master Services Agreement with Vericel under its BARDA contract for NexoBrid.
Why it matters — MDWD watchers would track progress of the EscharEx Phase III trial and the Vericel agreement, as these are key milestones in the company's pipeline and commercial partnerships.
MediWound Ltd. announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026, with a conference call and webcast scheduled for 8:30 a.m. Eastern Time.
Why it matters — The announcement signals the upcoming release of MediWound's quarterly financial performance, which MDWD watchers monitor for updates on the company's operational and revenue trends.
The 6 Wall Street analysts covering MediWound Ltd. have a median 12-month price target of $31, with estimates ranging from $22 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering MediWound Ltd., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediWound Ltd. 29 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, MediWound Ltd. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (80 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +128.6% from the last close, and Ticker Nerd's factor model ranks MediWound Ltd. 29 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MediWound Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $36 over the next 12 months.
MediWound Ltd. returned -27.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
MediWound Ltd. is an integrated biopharmaceutical company specializing in next-generation enzymatic therapeutics for non-surgical tissue repair.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript". MediWound Ltd. held its second-quarter 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The item confirms the call took place and provides access to the company's discussion of its quarterly results.
MediWound Ltd. is an integrated biopharmaceutical company specializing in next-generation enzymatic therapeutics for non-surgical tissue repair. The company develops, manufactures, and commercializes biologics that address unmet needs in severe burns, chronic and hard-to-heal wounds, and other indications. Its lead product, NexoBrid, is an FDA-approved orphan biologic for enzymatic eschar removal in deep partial and full-thickness thermal burns in adults and pediatric patients, offering a non-surgical alternative that preserves healthy tissue, accelerates healing, and reduces complications and costs. Pipeline candidates include EscharEx, an enzymatic debridement agent for chronic wounds such as venous leg ulcers, and MW005 for non-melanoma skin cancer treatment. MediWound Ltd. operates a cGMP-certified manufacturing facility in Yavne, Israel, supporting global commercialization through strategic partnerships in the U.S., Europe, Japan, Australia, and other markets. Headquartered in Yavne, Israel, the company serves hospitalized patients and wound care settings worldwide, advancing innovative solutions in the biotechnology sector.
121 employees · Israel · https://www.mediwound.com